Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00162513
Status:
WITHDRAWN
Last Update Posted:
2011-04-28
First Post:
2005-09-11
Brief Title:
Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia
Sponsor:
Hadassah Medical Organization
Organization:
Hadassah Medical Organization
Study Overview
Official Title:
Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia
Status:
WITHDRAWN
Status Verified Date:
2006-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
PI is no longer work at Hadassah
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Donors with CM will be solicited from a waiting list of patients awaiting BMT from the waiting list of MUD searches
Maximally matched donor will be searched for each eligible CML patient with a goal in mind to find other patients with CML that share both class I and class II determinants Sharing of one class I II will be considered eligible for participation in the study Peripheral blood and PBMC from the donors will be isolated washed and irradiated
The cells will be injected into the consenting patients intracutaneously at 2 weeks intervals for a total of 6 injections
Maximally matched donor will be searched for each eligible CML patient with a goal in mind to find other patients with CML that share both class I and class II determinants Sharing of one class I II will be considered eligible for participation in the study Peripheral blood and PBMC from the donors will be isolated washed and irradiated
The cells will be injected into the consenting patients intracutaneously at 2 weeks intervals for a total of 6 injections
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None